VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Male or female, 18-75 years old                    │ Male or female, 18-75 years old                    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has a diagnosis of WHO Group 1 PAH                 │ Has a diagnosis of WHO Group 1 PAH                 │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Right heart catheterization performed at Screening │ Right heart catheterization performed at Screening │     100 │
│ with results that are                              │ with results that are                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Mean pulmonary arterial pressure ≥25 mmHg (at      │ Mean pulmonary arterial pressure ≥25 mmHg (at      │     100 │
│ rest) and                                          │ rest) and                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pulmonary venous hypertension (measured as         │ Pulmonary venous hypertension (measured as         │     100 │
│ pulmonary capillary wedge pressure (PCWP) ≤15      │ pulmonary capillary wedge pressure (PCWP) ≤15      │         │
│ mmHg. If PCWP is not available, then mean left     │ mmHg. If PCWP is not available, then mean left     │         │
│ atrial pressure or left ventricular end-diastolic  │ atrial pressure or left ventricular end-diastolic  │         │
│ pressure ≤15 mmHg in the absence of left atrial    │ pressure ≤15 mmHg in the absence of left atrial    │         │
│ obstruction. and                                   │ obstruction. and                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pulmonary vascular resistance (PVR) ≥300 dyn•s/cm5 │ Pulmonary vascular resistance (PVR) ≥300 dyn•s/cm5 │     100 │
│ (3.75 Wood units)                                  │ (3.75 Wood units)                                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has WHO/NYHA-FC of II or III                       │ Has WHO/NYHA-FC of II or III                       │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Be on stable dose of at least one of the following │ Be on stable dose of at least one of the following │     100 │
│ PAH-specific therapies: endothelin receptor        │ PAH-specific therapies: endothelin receptor        │         │
│ antagonist, an agent acting on the nitric oxide    │ antagonist, an agent acting on the nitric oxide    │         │
│ pathway (phosphodiesterase type 5 inhibitor or     │ pathway (phosphodiesterase type 5 inhibitor or     │         │
│ soluble guanylate cyclase stimulator), and/or a    │ soluble guanylate cyclase stimulator), and/or a    │         │
│ prostacyclin or prostacyclin analog                │ prostacyclin or prostacyclin analog                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has a 6-minute walk distance that is ≥150 and ≤500 │ Has a 6-minute walk distance that is ≥150 and ≤500 │     100 │
│ meters                                             │ meters                                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Have a ventilation-perfusion scan that rules out   │ Have a ventilation-perfusion scan that rules out   │     100 │
│ thromboembolic disease                             │ thromboembolic disease                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Exclusions Related to Cardiovascular Disease       │ Exclusions Related to Cardiovascular Disease       │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of uncontrolled hypertension               │ History of uncontrolled hypertension               │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Persistent hypotension at Screening                │ Persistent hypotension at Screening                │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Evidence or history of left-sided heart disease    │ Evidence or history of left-sided heart disease    │     100 │
│ and/or clinically significant cardiac disease in   │ and/or clinically significant cardiac disease in   │         │
│ which pulmonary hypertension is more likely WHO    │ which pulmonary hypertension is more likely WHO    │         │
│ Group 2                                            │ Group 2                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Acute decompensated heart failure within 1 month   │ Acute decompensated heart failure within 1 month   │     100 │
│ of Screening                                       │ of Screening                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Recent initiation (\<8 weeks from Screening) or    │ Recent initiation (<8 weeks from Screening) or     │     100 │
│ planned initiation of cardiopulmonary              │ planned initiation of cardiopulmonary              │         │
│ rehabilitation exercise program                    │ rehabilitation exercise program                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Exclusions Related to Pulmonary Disease            │ Exclusions Related to Pulmonary Disease            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Newly diagnosed with PAH and not on PAH-specific   │ Newly diagnosed with PAH and not on PAH-specific   │     100 │
│ therapy                                            │ therapy                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pulmonary hypertension due to                      │ Pulmonary hypertension due to                      │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Uncorrected congenital systemic-to-pulmonary shunt │ Uncorrected congenital systemic-to-pulmonary shunt │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pulmonary veno-occlusive disease and/or pulmonary  │ Pulmonary veno-occlusive disease and/or pulmonary  │     100 │
│ capillary hemangiomatosis                          │ capillary hemangiomatosis                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Persistent pulmonary hypertension of the newborn   │ Persistent pulmonary hypertension of the newborn   │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ WHO clinical classification Groups 2-5             │ WHO clinical classification Groups 2-5             │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Evidence of significant airway and/or parenchymal  │ Evidence of significant airway and/or parenchymal  │     100 │
│ lung disease                                       │ lung disease                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Chronic infection related to tuberculosis or       │ Chronic infection related to tuberculosis or       │     100 │
│ fungal or mycobacterial disease                    │ fungal or mycobacterial disease                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Exclusions Based on Other Medical Conditions       │ Exclusions Based on Other Medical Conditions       │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Chronic infections including, but not limited to   │ Chronic infections including, but not limited to   │     100 │
│ tuberculosis (TB), hepatitis B virus (HBV) or      │ tuberculosis (TB), hepatitis B virus (HBV) or      │         │
│ hepatitis C virus (HCV)                            │ hepatitis C virus (HCV)                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of portal hypertension or chronic liver    │ History of portal hypertension or chronic liver    │     100 │
│ disease, including positive serology for infection │ disease, including positive serology for infection │         │
│ with HCV and/or HBV                                │ with HCV and/or HBV                                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Evidence of active infection requiring intravenous │ Evidence of active infection requiring intravenous │     100 │
│ or oral antibiotics within 4 weeks of Screening    │ or oral antibiotics within 4 weeks of Screening    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Body mass index ≥35.0 at Screening                 │ Body mass index ≥35.0 at Screening                 │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of obstructive sleep apnea                 │ History of obstructive sleep apnea                 │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of malignancy within the last 5 years,     │ History of malignancy within the last 5 years,     │     100 │
│ except nonmelanoma skin cancer and cervical        │ except nonmelanoma skin cancer and cervical        │         │
│ carcinoma in situ treated with curative intent     │ carcinoma in situ treated with curative intent     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Neuropsychiatric disorders/symptoms or             │ Neuropsychiatric disorders/symptoms or             │     100 │
│ psychological conditions                           │ psychological conditions                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnancy or breast-feeding                        │ Pregnancy or breast-feeding                        │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Prior treatment with B cell or lymphocyte-         │ Prior treatment with B cell or lymphocyte-         │     100 │
│ depleting agents (eg, rituximab, Campath)          │ depleting agents (eg, rituximab, Campath)          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Exclusions Based on Concomitant Medication Use     │ Exclusions Based on Concomitant Medication Use     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Concurrent regular use of another leukotriene      │ Concurrent regular use of another leukotriene      │     100 │
│ pathway inhibitor, including over-the-counter      │ pathway inhibitor, including over-the-counter      │         │
│ medications or herbal remedies                     │ medications or herbal remedies                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Exclusions Based on Laboratory Values              │ Exclusions Based on Laboratory Values              │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Significant/chronic renal insufficiency            │ Significant/chronic renal insufficiency            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hepatic dysfunction as defined by Child-Pugh Class │ Hepatic dysfunction as defined by Child-Pugh Class │     100 │
│ B or C                                             │ B or C                                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Transaminases (alanine transaminase, aspartate     │ Transaminases (alanine transaminase, aspartate     │      99 │
│ transaminase) levels \>3 × upper limit of normal   │ transaminase) levels >3 × upper limit of normal    │         │
│ (ULN) and/or bilirubin level \>2 × ULN             │ (ULN) and/or bilirubin level >2 × ULN              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Absolute neutrophil count \<1500 mm3               │ Absolute neutrophil count <1500 mm3                │      99 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hemoglobin concentration \<9 g/dL at Screening     │ Hemoglobin concentration <9 g/dL at Screening      │      99 │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤═════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                   │   Score │
╞═══════════════════════════════════╪═════════════════════════════════╪═════════╡
│ Must have minimum age of 18 Years │ Male or female, 18-75 years old │      47 │
├───────────────────────────────────┼─────────────────────────────────┼─────────┤
│ Must have maximum age of 75 Years │ Male or female, 18-75 years old │      47 │
╘═══════════════════════════════════╧═════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 99
Average Levenshtein Ratio of individual lines: 97.57777777777778
OverAll Ratio: 98.28888888888889
